Earnings History Data for Kiniksa Pharmaceuticals, Ltd. (KNSA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-10-2024	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,950	-0.18	-0.01	-0.20	Kiniksa Pharmaceuticals GAAP EPS of -$0.18 misses by $0.21, revenue of $112.21M beats by $0.61M [10/29/2024 7:34 AM]	23.32	-4.27 (-15.48%)	28.30	0.71 (2.57%)	14.12 - 28.15	898,782	230,000	18,682
Kiniksa Pharmaceuticals Q3 2024 Earnings Preview [10/28/2024 1:47 PM] Kiniksa Pharmaceuticals GAAP EPS of -$0.18 misses by $0.21, revenue of $112.21M beats by $0.61M [10/29/2024 7:34 AM] Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution [2024-10-29 07:30AM] What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings [Oct-28-24 09:05AM] Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis [Oct-28-24 08:00AM]
23-07-2024	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,500	-0.06	-0.09	-0.02	Kiniksa Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01, revenue of $108.63M beats by $17.36M [7/23/2024 7:32 AM]	26.35	4.96 (23.19%)	23.30	1.91 (8.93%)	14.12 - 27.88	3,606,438	420,000	24,270
Kiniksa Pharmaceuticals Q2 2024 Earnings Preview [7/22/2024 2:20 PM] Kiniksa Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01, revenue of $108.63M beats by $17.36M [7/23/2024 7:32 AM]
23-04-2024	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,190	-0.25	-0.14	-0.18	Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook [4/23/2024 7:37 AM]	17.72	0.62 (3.66%)	17.55	0.46 (2.66%)	10.65 - 22.09	475,578	340,000	719
Kiniksa Pharmaceuticals Q1 2024 Earnings Preview [4/22/2024 5:05 PM] Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook [4/23/2024 7:37 AM]
28-02-2024	PM		KNSA	Kiniksa Pharmaceuticals	1,407	0.04	-0.11	0.00	Kiniksa Pharmaceuticals GAAP EPS of $0.35 beats by $0.49, revenue of $83.4M beats by $11.13M [2/28/2024 7:31 AM]	20.28	-0.61 (-2.92%)	21.70	0.81 (3.88%)	10.29 - 21.98	435,088	290,000	5,714
Kiniksa Pharmaceuticals Q4 2023 Earnings Preview [2/27/2024 12:25 PM] Kiniksa Pharmaceuticals GAAP EPS of $0.35 beats by $0.49, revenue of $83.4M beats by $11.13M [2/28/2024 7:31 AM]
31-10-2023	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,060	-0.20	-0.18	0.67	Kiniksa Pharmaceuticals GAAP EPS of -$0.20 misses by $0.03, revenue of $67.05M beats by $2.6M [10/31/2023 7:44 AM]	15.25	-0.43 (-2.74%)	14.95	-0.73 (-4.66%)	10.29 - 20.65	728,569	340,000	13,751
Kiniksa Pharmaceuticals Q3 2023 Earnings Preview [10/30/2023 11:27 AM] Kiniksa Pharmaceuticals GAAP EPS of -$0.20 misses by $0.03, revenue of $67.05M beats by $2.6M [10/31/2023 7:44 AM]
25-07-2023	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	2,180	-0.02	-0.16	-0.29	Kiniksa Pharmaceuticals GAAP EPS of $0.21 beats by $0.38, revenue of $71.47M beats by $19.27M [7/25/2023 7:36 AM]	19.47	4.53 (30.32%)	16.98	2.04 (13.65%)	9.63 - 20.00	4,315,740	480,000	21,653
Kiniksa Pharmaceuticals Q2 2023 Earnings Preview [7/24/2023 12:55 PM] Kiniksa Pharmaceuticals GAAP EPS of $0.21 beats by $0.38, revenue of $71.47M beats by $19.27M [7/25/2023 7:36 AM] Kiniksa Pharma soars 33% on strong quarterly results [7/25/2023 1:23 PM]
01-11-2022	PM	7:30 AM ET (Nov 1)	KNSA	Kiniksa Pharmaceuticals	814.00	0.67	0.38	0.00	Kiniksa Pharmaceuticals GAAP EPS of $3.18, revenue of $99.13M [11/1/2022 8:44 AM]	12.87	1.45 (12.70%)	11.74	0.32 (2.80%)	7.36 - 15.24	1,134,394	260,000	742
Kiniksa Pharmaceuticals GAAP EPS of $3.18, revenue of $99.13M [11/1/2022 8:44 AM] Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-01-22 08:00AM] Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022 [Oct-31-22 04:01PM]
03-08-2022	PM	8:00 AM ET (Aug 3)	KNSA	Kiniksa Pharmaceuticals, Ltd.	760.65	-0.29	-0.43	-0.61	Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance [8/3/2022 8:09 AM]	10.66	0.69 (6.92%)	10.45	0.48 (4.81%)	7.36 - 15.92	1,956,203	200,000	75,026
Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance [8/3/2022 8:09 AM] Kiniksa in licensing pact with Roche unit Genentech for fibrosis candidate [8/3/2022 12:34 PM] Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update [Aug-03-22 07:30AM] Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab [Aug-03-22 07:29AM] Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022 [Aug-02-22 04:01PM]
01-11-2021	PM	8:00 AM ET (Nov 1)	KNSA	Kiniksa Pharmaceuticals	750.00	-0.44	-0.63	0.00	Kiniksa Pharmaceuticals EPS beats by $0.19, beats on revenue [11/1/2021 8:05 AM]	12.72	2.33 (22.43%)	10.90	0.51 (4.91%)	10.30 - 24.70	1,095,361	230,000	3,327
Kiniksa Pharmaceuticals EPS beats by $0.19, beats on revenue [11/1/2021 8:05 AM] Kiniksa posts a record gain as outlook beats estimates [11/1/2021 3:22 PM] Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution [Nov-01-21 08:00AM] Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021 [Oct-29-21 04:01PM] Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates [Nov-01-21 09:15AM]
03-08-2021	PM	8:00 AM ET (Aug 3)	KNSA	Kiniksa Pharmaceuticals, Ltd.	1,050	-0.61	-0.69	-0.65	Kiniksa Pharmaceuticals EPS misses by $0.66, beats on revenue [8/3/2021 8:22 AM]	13.51	-2.72 (-16.79%)	15.85	-0.38 (-2.34%)	12.63 - 24.70	2,518,562	540,000	24,498
Kiniksa Pharmaceuticals EPS misses by $0.66, beats on revenue [8/3/2021 8:22 AM] Kiniksa reports positive data for COVID-19 respiratory syndrome candidate [8/3/2021 4:01 PM] Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference [Aug-02-21 04:01PM] Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity [Aug-03-21 08:00AM] Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates [Aug-03-21 09:15AM]
04-05-2021	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,150	-0.72	-0.73	-0.48	Kiniksa Pharmaceuticals EPS misses by $0.08 [5/4/2021 8:13 AM]	15.78	-0.74 (-4.48%)	15.78	0.0 (0.00%)	14.51 - 28.67	292,301	290,000	23,031
Kiniksa Pharmaceuticals EPS misses by $0.08 [5/4/2021 8:13 AM] Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity [May-04-21 08:00AM] Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404 [May-04-21 07:59AM]
23-02-2021	PM		KNSA	Kiniksa Pharmaceuticals, Ltd.	1,590	-0.79	-0.61	-0.58	Kiniksa Pharmaceuticals EPS misses by $0.18 [2/23/2021 8:08 AM]	20.85	-1.02 (-4.66%)	21.90	0.03 (0.14%)	10.30 - 28.67	256,718	392,776	140
Kiniksa Pharmaceuticals EPS misses by $0.18 [2/23/2021 8:08 AM]